Top-Line Preliminary Data From Phase II/III Study of Corthera's Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008

Tuesday, November 4, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

SAN MATEO, Calif., Nov. 3 Top-line preliminary data from aPhase II/III clinical trial of Corthera's investigational drug relaxin for thetreatment of acute heart failure will be presented next week at a satellitesymposium at the American Heart Association's (AHA) Scientific Sessions 2008in New Orleans.

John R. Teerlink, M.D., Professor of Medicine, University of CaliforniaSan Francisco, will present the data from the multicenter, internationalPre/RELAX-AHF study as part of a symposium entitled "Tailoring Therapy toPresentation" that will focus on new approaches to the treatment of acuteheart failure. The symposium will take place from 6 a.m. CST to 8 a.m. CST onMonday, Nov. 10, in the Grand Ballroom of the Sheraton New Orleans Hotel.

According to the AHA, heart failure is a costly syndrome contributing tomore than 3 million hospitalizations each year in the U.S. The great majorityof patients with acute heart failure have fluid accumulation in the lungs(congestion) that causes shortness of breath and other complications. Forthese patients, the current standard of care includes diuretics andvasodilators. Both of these classes of agents have been associated with renalimpairment, hypotension and adverse outcomes.

About Relaxin

Relaxin is a naturally occurring peptide hormone that acts as a systemicand renal vasodilator. Elevated levels of relaxin modulate increases in renaland cardiac function that meet the increased hemodynamic demands of pregnancy.Consistent with this natural role of the hormone, pharmaceuticallymanufactured relaxin has been shown to have these effects in multiple humanstudies of men and non-pregnant women. Data from a pilot study in patientswith heart failure support the expectation that these effects may bebeneficial in relieving the signs and symptoms of heart failure.

About Corthera

Corthera Inc. is a biopharmaceutical company committed to acquiring,developing and commercializing therapies for illnesses in the acute caresetting. Corthera's lead product candidate, relaxin, is currently beingevaluated in clinical trials for acute heart failure. Corthera has worldwiderights to develop and commercialize relaxin.

About the Satellite Symposium

Dr. Teerlink is the chair of the symposium and co-principal investigatorof the Pre/RELAX-AHF study. Additional speakers will include Dr. Marco Metra,associate professor of cardiology, Department of Experimental and AppliedMedicine, University of Brescia, Italy, and Dr. Gregg Fonarow, professor ofmedicine, UCLA School of Medicine. Dr. Metra is also co-principalinvestigator of the Pre/RELAX-AHF Study. Additional symposium information canbe found at: Contact: Andreas Marathovouniotis or Ian Stone Russo Partners 212.845.4235 or 619.814.3510

SOURCE Corthera

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store